About us
Switchpoint Bio is decoding the molecular switchpoints that drive human health and disease. The choices our cells make — which genes to activate, how to respond to environment and exposure, when to mount immune defenses — are governed by epigenetic mechanisms.
We bring together epigenomics and AI to turn that biology into decision-grade evidence for drug development and clinical research.
Founded by pioneers in single-cell biology, epigenetics and genomics, we operate across Helsinki and Boston.
Founding Team
Founded by pioneers in single-cell biology, epigenetics and genomics, we operate across Helsinki and Boston.
Niilo
Färkkilä, PhD
CCO & Co-founder
Senior pharma executive with leadership roles at Amgen, GSK and Pfizer across multiple therapy areas.
Deep background in real-world evidence, digital health and health economics.
Expert in pharma partnerships, commercialization strategy and market access for therapeutics.
Jason
Buenrostro, PhD
Scientific Advisor &
Co-founder
Pioneer of epigenomics and single-cell genomics, inventor of ATAC-seq, one of the field's foundational technologies.
Professor at Harvard and Director of the Epigenomics Program at the Broad Institute.
MacArthur Fellow and global leader in single-cell and immune epigenomics, with landmark publications in Nature, Science and Cell.
Mitja
Kurki, PhD
Scientific Advisor &
Co-founder
Founded and led the FinnGen Analytics team, architecting a genomics platform spanning over 500,000 individuals.
Broad Institute leader delivering genomics infrastructure and data platforms for pharma partners.
Expert in population-scale genomics and drug discovery enablement.
Mitja on LinkedIn
Jussi
Paananen, PhD
CTO & Co-founder
Built Blueprint Genetics' technology and product organization, then led Global Bioinformatics at Quest Diagnostics.
Previously a technology leader at Meru Health and a scientist at the Broad Institute.
Has shipped AI, genomics and data platforms in regulated clinical environments throughout his career.
Samuel
Myllykangas, PhD
CEO & Co-founder
Founded and led Blueprint Genetics from inception through its acquisition by Quest Diagnostics, then served as VP at Quest Diagnostics.
Stanford-trained genomic scientist.
Built a global, regulated genomics platform from innovation to commercial scale — now building the next.
Samuel on LinkedIn
Why we exist
To improve lives by decoding the biology of health and disease — the deeper that understanding goes, the sooner disease can be treated, and ultimately prevented.
What we are building
A new way to read immune biology at scale — turning cellular signal into biomarkers, patient segments, and mechanism insight for therapeutic development.